Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

ded our original expectation for enhancing ApoA-l production in humans," stated Donald J. McCaffrey, President and CEO of Resverlogix. "We know that the enhancement of ApoA-l and key RCT particles in the body is widely recognized by international experts as the necessary markers to potentially impact atherosclerosis regression. Hence, we have achieved another critically important clinical milestone for our Company," noted McCaffrey.

The Phase 1b/2a trial was a double blind safety and tolerance study which investigated the pharmacokinetics and also early pharmacodynamics effects of RVX-208. A total of 72 subjects enrolled in the trial. The study had three arms, a low dose arm with 24 subjects, a dose-escalation arm with 24 subjects, and a third high dose arm with 24 subjects. This trial also examined early markers for reverse cholesterol transport such as ApoA-l, HDL-c, pre-beta HDL and alpha HDL subparticles. Approximately half of the subjects had low levels of baseline HDL cholesterol.

Highlights from the study are as follows:

    -   The primary endpoint, plasma ApoA-I increase compared to placebo,
        achieved a range in all subjects of 5.1% - 10.4% in all doses at days
        8 and 28 respectively.
    -   At the lowest dose of 1mg/kg b.i.d. in subjects with low levels of
        HDL-c, plasma ApoA-l increases reached statistical significance of
        5.7% (p(less than)0.05) at day 8 and 7.8% (p(less than)0.05) at
        day 28.
    -   A critical RCT functionality marker, alpha-1 HDL particles,
        illustrated highly statistical significance with an increase of
        46.7% (p(less than)0.004), in all subjects and
        57.2% (p(less than)0.02) in the low dose arm over placebo at day 28.
    -   Pharmacokinetic parameters of RVX-208 were dose dependant with oral
        administration.
    -   RVX-208 was shown to be compatible with simvastatin (40mg).
    -   Seventy out of seventy two subjects completed the tria
'/>"/>
Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Hill Road in Menlo Park, Calif., which is the venture ... of a "boomlet" in deal-making. Technology firms that only a ... a venture capitalist are now entertaining multiple offers to finance ... company, XenSource, had seven solid investment offers in three weeks. ...
... StrandVision LLC , an online digital signage company, ... supplier in Silverdale, Wash., on Monday announced that they ... agreement, StrandVision resellers and customers will be provided with ... where they will receive information that will help them ...
... in the chemistry department at the University of Wisconsin-Eau ... from the National Science Foundation in recent weeks ... support faculty-student research. , ,"This is a huge influx ... have a significant impact on what we can do ...
Cached Biology Technology:Wisconsin early-stage companies must position themselves to get capital 2Wisconsin early-stage companies must position themselves to get capital 3UW-Eau Claire chemistry faculty get $600,000 in NSF grants 2UW-Eau Claire chemistry faculty get $600,000 in NSF grants 3
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... Societies for Experimental Biology (FASEB) announces the opening ... Mechanism and Regulation of Prokaryotic Transcription. ... and Regulation of Prokaryotic Transcription will convene Sunday, ... Transcription Meeting," first held in 1991, has emerged ...
... Since the mid-nineteenth century, maps have helped elucidate the ... Yet today,s global mapping of infectious diseases is considerably ... of potential outbreaks, according to a new systematic mapping ... humans., Of the 355 infectious diseases assessed in the ...
... every time a cell divides and replicates. Depending on ... Many proteins are involved in everyday DNA repair, but ... and cancer can occur. Cells have two complicated ways ... of the entire genome., Roger A. Greenberg, M.D., Ph.D., ...
Cached Biology News:Avoiding a cartography catastrophe 2Changes to DNA on-off switches affect cells' ability to repair breaks, respond to chemotherapy 2
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Biology Products: